Trachoma control

Authors’ reply to Solomon writing on behalf of 18 others

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e2588 (Published 10 April 2012)
Cite this as: BMJ 2012;344:e2588

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. R Baltussen, senior researcher1,
  2. A Smith, honorary professor2,
  3. D Chisholm, health economist3
  1. 1Department of Primary and Community Care, Radboud University, Nijmegen Medical Centre, Netherlands
  2. 2International Centre for Evidence on Disability, London School of Hygiene and Tropical Medicine, London, UK
  3. 3Department of Health Systems Financing, WHO, Geneva, Switzerland
  1. r.baltussen{at}elg.umcn.nl

Solomon and colleagues inappropriately label our analysis of trachoma control erroneous, but their comments are largely related to methodological issues in (standardised WHO-CHOICE) cost effectiveness analysis and present gaps in knowledge.1 2

Firstly, mass treatment with antibiotics of all residents is probably more effective and costly than treatment of children. Whether the first intervention is cost effective according to international thresholds, and more cost effective …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL